Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses

Author(s):
Capelleveen, J.C. van; Kastelein, J.J.P.; Zwinderman, A.H.; Deventer, S.J.H. van; Collins, H.L.; Adelman, S.J.; Round, P.; Ford, J.; Rader, D.J.; Hovingh, G.K.
Published
2016
Publication type
Article / Letter to editor

Abstract

CONCLUSION: TA-8995 dose dependently increased not only total and non-ABCAl-specific CEC but also ABCAl-specific CEC and preBeta-1 HDL particle levels. These findings suggest that TA-8995 not only increases HDL-C levels but also promotes functional properties of HDL particles. This CETP inhibitor driven preBeta-1 HDL increase is an important predictor of both ABCA1 and total CEC increase, independent of HDL-C increase. Whether these changes in HDL particle composition and functionality have a beneficial effect on cardiovascular outcome requires formal testing in a cardiovascular outcome trial. (C) 2016 National Lipid Association. All rights reserved.

TA-8995CETP inhibitorCholesterol efflux capacityHDLPre-Beta1 HDL
Date issued
2016-10-01
Language
English
Publisher
ELSEVIER SCIENCE INC
Is part of
Journal of Clinical Lipidology (2016), Vol. 10, no. 5, p. 1137-1144
hdl
1887/117232
doi
10.1016/j.jacl.2016.06.006